Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients

Clinical Nutrition

Volumn 35, Issue 3, 2016, Pages 724-730

  Anandavadivelan, Poorna ^a   Brismar, Torkel B ^a   Nilsson, Magnus ^a   Johar, Asif M ^a   Martin, Lena ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Body composition; Chemotherapy; Oesophageal cancer; Sarcopenia; Sarcopenic obesity

Indexed keywords

CISPLATIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADIPOSE TISSUE INDEX; ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY MASS; CANCER ADJUVANT THERAPY; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; ESOPHAGUS CANCER; FAT MASS; FEMALE; HIGH RISK POPULATION; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; MUSCLE MASS; OBESITY; PHASE 3 CLINICAL TRIAL; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SARCOPENIA; SARCOPENIC OBESITY; UNDERWEIGHT; ADENOCARCINOMA; CACHEXIA; CANCER STAGING; CARCINOMA; CHEMICALLY INDUCED; CHEMORADIOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DOSE RESPONSE; ESOPHAGUS TUMOR; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; SWEDEN; UNIVERSITY HOSPITAL; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; CACHEXIA; CARCINOMA; CHEMORADIOTHERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OBESITY; OVERWEIGHT; PILOT PROJECTS; RISK FACTORS; SARCOPENIA; SWEDEN;

EID: 84930609028     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2015.05.011     Document Type: Article

References (50)

1. Lagergren J., Bergstrom R., Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999, 130(11):883-890.
2. Hoyo C., Cook M.B., Kamangar F., Freedman N.D., Whiteman D.C., Bernstein L., et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the international BEACON consortium. Int J Epidemiol 2012, 41(6):1706-1718.
3. Laviano A., Meguid M.M. Nutritional issues in cancer management. Nutr (Burbank, Los Angel Cty Calif 1996, 12(5):358-371.
4. Martin L., Lagergren J., Lindblad M., Rouvelas I., Lagergren P. Malnutrition after oesophageal cancer surgery in Sweden. Br J Surg 2007, 94(12):1496-1500.
5. Bozzetti F. Nutritional support in patients with oesophageal cancer. supportive care in cancer. Off J Multinatl Assoc of Support Care in Cancer 2010, 18(2):S41-S50.
6. Martin L., Jia C., Rouvelas I., Lagergren P. Risk factors for malnutrition after oesophageal and cardia cancer surgery. Br J Surg 2008, 95(11):1362-1368.
7. Daly J.M., Fry W.A., Little A.G., Winchester D.P., McKee R.F., Stewart A.K., et al. Esophageal cancer: results of an American college of surgeons patient care evaluation study. J Am Coll Surg 2000, 190(5):562-572. discussion 72-3.
8. Fearon K., Strasser F., Anker S.D., Bosaeus I., Bruera E., Fainsinger R.L., et al. Definition and classification of cancer cachexia: an international consensus. lancet Oncol 2011, 12(5):489-495.
9. Tan B.H.B.L., Martin L., Baracos V.E., Fearon K.C. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009, 15(22):6973-6979.
10. Prado C.M., Lieffers J.R., McCargar L.J., Reiman T., Sawyer M.B., Martin L., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. lancet Oncol 2008, 9(7):629-635.
11. Thibault R.G.L., Pichard C. Body composition: why, when and for who?. Clin Nutr 2013, 31(4):435-447.
12. Martin L., Birdsell L., Macdonald N., Reiman T., Clandinin M.T., McCargar L.J., et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013, 31(12):1539-1547.
13. Cruz-Jentoft A.J., Baeyens J.P., Bauer J.M., Boirie Y., Cederholm T., Landi F., et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working group on Sarcopenia in older people. Age Ageing 2010, 39(4):412-423.
14. Dewys W.D., Begg C., Lavin P.T., Band P.R., Bennett J.M., Bertino J.R., et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern cooperative oncology group. Am J Med 1980, 69(4):491-497.
15. Andreyev H.J., Norman A.R., Oates J., Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?. Eur J Cancer 1998, 34(4):503-509. [Oxford, England: 1990].
16. Adenis A., Tresch E., Dewas S., Romano O., Messager M., Amela E., et al. Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome. BMC Cancer 2013, 13:413.
17. Prado C.M., Baracos V.E., McCargar L.J., Reiman T., Mourtzakis M., Tonkin K., et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009, 15(8):2920-2926.
18. Prado C.M., Lima I.S., Baracos V.E., Bies R.R., McCargar L.J., Reiman T., et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 2011, 67(1):93-101.
19. Prado C.M., Baracos V.E., McCargar L.J., Mourtzakis M., Mulder K.E., Reiman T., et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007, 13(11):3264-3268.
20. Barret M., Antoun S., Dalban C., Malka D., Mansourbakht T., Zaanan A., et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 2014, 66(4):583-589.
21. Antoun S., Baracos V.E., Birdsell L., Escudier B., Sawyer M.B. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010, 21(8):1594-1598.
22. Antoun S., Lanoy E., Iacovelli R., Albiges-Sauvin L., Loriot Y., Merad-Taoufik M., et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer 2013, 119(18):3377-3384.
23. Harimoto N., Shirabe K., Yamashita Y.I., Ikegami T., Yoshizumi T., Soejima Y., et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg 2013, 100(11):1523-1530.
24. Lieffers J.R., Bathe O.F., Fassbender K., Winget M., Baracos V.E. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 2012, 107(6):931-936.
25. Study protocol for resectabel cancer of the esophagus and gastro-esophageal junction. [2014-04-07]. Available from: . http://www.google.se/url?sa=t&rct=j&q=&esrc=s&source=web&cd=7&ved=0CFcQFjAG&url=http%3A%2F%2Fneores.org%2Fdoc%2FRes_studie_protokoll_20090607.doc&ei=9RdeU7foHofJ4wSZ-4D4Bw&usg=AFQjCNHyQw-1D2G9n07QVR4dKftjZkE42g&sig2=_r18c2CgPaCzQYtxt7en-A&bvm=bv.65397613,d.bGE&cad=rja.
26. NIHImage [2014-12-15]. Available from: . http://imagej.nih.gov/ij/.
27. Mitsiopoulos N., Baumgartner R.N., Heymsfield S.B., Lyons W., Gallagher D., Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiology 1998, 85(1):115-122.
28. Kvist H., Chowdhury B., Grangard U., Tylen U., Sjostrom L. Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. Am J Clin Nutr 1988, 48(6):1351-1361.
29. Aubrey J., Esfandiari N., Baracos V.E., Buteau F.A., Frenette J., Putman C.T., et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol 2014, 210(3):489-497.
30. Mourtzakis M., Prado C.M., Lieffers J.R., Reiman T., McCargar L.J., Baracos V.E. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol, Nutr Metab Physiologie Appl, Nutr Metab 2008, 33(5):997-1006.
31. Lagergren J., Lagergren P. Oesophageal cancer. BMJ 2010, 341.
32. Jacquelin-Ravel N., Pichard C. Clinical nutrition, body composition and oncology: a critical literature review of the synergies. Crit Rev Oncol/Hematol 2012, 84(1):37-46.
33. Deans D.A., Tan B.H., Wigmore S.J., Ross J.A., de Beaux A.C., Paterson-Brown S., et al. The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br J Cancer 2009, 100(1):63-69.
34. Tan B.H., Birdsell L.A., Martin L., Baracos V.E., Fearon K.C. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009, 15(22):6973-6979.
35. Awad S., Tan B.H., Cui H., Bhalla A., Fearon K.C., Parsons S.L., et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr 2012, 31(1):74-77.
36. Yip C., Goh V., Davies A., Gossage J., Mitchell-Hay R., Hynes O., et al. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol 2014, 24:998-1005.
37. Prado C.M., Birdsell L.A., Baracos V.E. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 2009, 3(4):269-275.
38. 2 consumption in man after prolonged bed rest. J Physiol 1997, 501(Pt 3):677-686.
39. Shen W., Punyanitya M., Wang Z., Gallagher D., St-Onge M.P., Albu J., et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiology 2004, 97(6):2333-2338.
40. Goodpaster B.H., Thaete F.L., Kelley D.E. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr 2000, 71(4):885-892.
41. Taaffe D.R., Henwood T.R., Nalls M.A., Walker D.G., Lang T.F., Harris T.B. Alterations in muscle attenuation following detraining and retraining in resistance-trained older adults. Gerontology 2009, 55(2):217-223.
42. Murphy R.A., Mourtzakis M., Chu Q.S., Baracos V.E., Reiman T., Mazurak V.C. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 2011, 117(8):1775-1782.
43. Goodpaster B.H., Kelley D.E., Thaete F.L., He J., Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol 2000, 89(1):104-110.
44. Larson-Meyer D.E., Smith S.R., Heilbronn L.K., Kelley D.E., Ravussin E., Newcomer B.R. Muscle-associated triglyceride measured by computed tomography and magnetic resonance spectroscopy. Obes (Silver Spring, Md) 2006, 14(1):73-87.
45. Stephens N.A., Skipworth R.J., Macdonald A.J., Greig C.A., Ross J.A., Fearon K.C. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J cachexia, Sarcopenia Muscle 2011, 2(2):111-117.
46. Irigaray P., Newby J.A., Lacomme S., Belpomme D. Overweight/obesity and cancer genesis: more than a biological link. Biomed Pharmacother = Biomedecine Pharmacother 2007, 61(10):665-678.
47. Tao W., Lagergren J. Clinical management of obese patients with cancer. Nat Rev Clin Oncol 2013, 10(9):519-533.
48. Thibault R., Pichard C. The evaluation of body composition: a useful tool for clinical practice. Ann Nutr Metab 2012, 60(1):6-16.
49. Zinna E.M., Yarasheski K.E. Exercise treatment to counteract protein wasting of chronic diseases. Curr Opin Clin Nutr metabolic Care 2003, 6(1):87-93.
50. Hojan K., Milecki P., Molinska-Glura M., Roszak A., Leszczynski P. Effect of physical activity on bone strength and body composition in breast cancer premenopausal women during endocrine therapy. Eur J Phys Rehabil Med 2013, 49(3):331-339.